Arixtra adds treatment indications
Executive Summary
Sanofi-Synthelabo's antithrombotic Arixtra (fondaparinux) clears FDA May 28 for treatment of deep vein thrombosis and pulmonary embolism. The product, previously approved for prophylactic use in patients undergoing hip fracture surgery and hip or knee replacement, is being divested to GlaxoSmithKline in conjunction with Sanofi's pending acquisition of Aventis (1"The Pink Sheet" April 19, 2004, p. 18)...